Dr. Desai reviews findings from a post-hoc analysis of the TRuE-V1 and TRuE-V2 clinical trials, focusing on the efficacy and durability of treatment with Ruxolitinib> cream 1.5% in patients with Vitiligo, particularly those with facial involvement.
His discussion highlights how treatment responses may vary across characteristic patient subgroups and examines the long-term repigmentation outcomes observed with continued therapy.
Topics Covered
- Post-hoc analysis findings from the TRuE-V1/TRuE-V2 trials
- Efficacy of ruxolitinib cream 1.5% in facial vitiligo
- Longevity and durability of repigmentation outcomes
- Understanding subgroup responses in vitiligo treatment
Explore Related Resources